Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Marker Therapeutics (MRKR) over the last 10 years, with Q3 2025 value amounting to -$2.0 million.

  • Marker Therapeutics' Income from Continuing Operations rose 1341.01% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.4 million, marking a year-over-year decrease of 4917.25%. This contributed to the annual value of -$10.7 million for FY2024, which is 2359.96% up from last year.
  • Per Marker Therapeutics' latest filing, its Income from Continuing Operations stood at -$2.0 million for Q3 2025, which was up 1341.01% from -$4.1 million recorded in Q2 2025.
  • Over the past 5 years, Marker Therapeutics' Income from Continuing Operations peaked at -$2.0 million during Q3 2025, and registered a low of -$9.8 million during Q1 2022.
  • For the 4-year period, Marker Therapeutics' Income from Continuing Operations averaged around -$3.9 million, with its median value being -$3.8 million (2024).
  • As far as peak fluctuations go, Marker Therapeutics' Income from Continuing Operations skyrocketed by 5685.27% in 2023, and later crashed by 8849.14% in 2025.
  • Marker Therapeutics' Income from Continuing Operations (Quarter) stood at -$2.9 million in 2022, then grew by 6.58% to -$2.7 million in 2023, then plummeted by 38.42% to -$3.8 million in 2024, then skyrocketed by 47.23% to -$2.0 million in 2025.
  • Its Income from Continuing Operations stands at -$2.0 million for Q3 2025, versus -$4.1 million for Q2 2025 and -$4.4 million for Q1 2025.